THE DEAL, AT A GLANCE

Alethio Therapeutics

From the announcement

Medicine development

What it doesAlethio Therapeutics is dedicated to developing innovative, disease-modifying therapies for chronic blood cancers.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗

02What happenedAlethio Therapeutics raised Series A, announced 2026-11-05From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗

03Why it mattersAlethio Therapeutics raised a $90M Series A to advance therapies for myeloproliferative neoplasms, placing the round at the 76th percentile by size among tracked…From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗

Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Alethio Therapeutics · Financing Record

Explore source-linked visual explanations for Alethio Therapeutics. Unsupported claims are withheld while source review continues.

Record 15378 · Recorded date: 2026-11-05

What it does

Alethio Therapeutics: illustrative category image — Illustrative image (software ui), not Alethio Therapeutics's product · Kanika Murarka / CC BY-SA 4.0

Founded as a University of Oxford spin-out by two globally recognised haematologist physician-scientists, Alethio builds on pioneering research that has advanced the understanding of these diseases.

Source: alethiotherapeutics.com ↗

Open record 15378 →

Explore company records →